Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.

Merck Enters Alzheimer’s Collaboration with Cerevance

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

Amgen Will Acquire Chemocentryx in $4 Billion Deal

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

Synthego Aims to Accelerate Drug Discovery with New Engineered Cell Libraries

Brian Carlin is global manager of pharmaceutical research and development at FMC-Biopolymer (Princeton, NJ).

George Collins is vice president, Vanderbilt Chemicals LLC. 

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting and a member of Pharmaceutical Technology’s editorial advisory board.

David Schoneker is president, Black Diamond Regulatory Consulting, LLC

Jennifer Putnam is AR&D supervisor II, Perrigo

Joseph Zeleznik is manager, technical & regulatory affairs at Meggle USA.

Katherine Ulman is a Global Regulatory Compliance Manager at Dow Corning.

Stacey Bremer is Director, Product Stewardship Medical at Celanese.

This article reviews sources of excipient variability, including raw materials and processing, both of which may vary from supplier to supplier and from plant to plant for a single manufacturer.

Mitigating the Risk from Excipient Variability

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Industry is adapting to the increasing complexity and poor solubility and bioavailability of molecules in the pipeline.

Adapting to Solubility/Bioavailability Challenges

Sergio A. Bernal-Chávez, PhD, is research associate at Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México.

Sergio Alcalá-Alcalá, PhD, is principal scientist at Laboratorio de Tecnología Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, México.

Doris Cerecedo, PhD, is principal scientist at Laboratorio de Hematobiología, Escuela Nacional de Medicina y Homeopatía, Sección de Estudios de Posgrado, Instituto Politécnico Nacional, Ciudad de México.

, is principal scientist at Laboratorio de Investigación y Posgrado en Tecnología Farmacéutica (L-322, Campo 1), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México.

The purpose of this article was to demonstrate the application of a new thermogelling matrix in the healing of wounds.

Thermogelling Matrix-Containing Platelet Lysate-Loaded Elastic Liposomes as a Potential Treatment of Wounds

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Further advances in construct design and manufacturing scalability are still needed.

Progress in the Development of CAR NK-Cell Therapies

Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.

Bio-Rad Expands Portfolio of Anti-Idiotypic Antibodies

The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.

Oregon Freeze Dry Opens $7.5 Million Biopharma Facility

Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment. 

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development